Comment on:: Evans JMM!, Ogston SA!, Emslie-Smith A!, Morris AD! (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes:: a comparison of patients treated with sulfonylureas and metformin.: Diabetologia 49:930-936

被引：3

作者：

Raccah, D. ^{[1
]}

机构：

[1] Univ Hosp Sainte Marguerite, Dept Diabetol, F-13009 Marseille, France

来源：

DIABETOLOGIA | 2007年 / 50卷 / 05期

关键词：

Metformin; Rosiglitazone; Sulfonylurea; Glibenclamide; Chlorpropamide;

D O I：

10.1007/s00125-007-0630-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1109 / 1110

页数：2

共 10 条

[1] Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin [J].

Evans, JMM ;

Ogston, SA ;

Emslie-Smith, A ;

Morris, AD .

DIABETOLOGIA, 2006, 49 (05) :930-936

[2] Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes [J].

Johnson, JA ;

Simpson, SH ;

Toth, EL ;

Majumdar, SR .

DIABETIC MEDICINE, 2005, 22 (04) :497-502

[3] Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes [J].

Johnson, JA ;

Majumdar, SR ;

Simpson, SH ;

Toth, EL .

DIABETES CARE, 2002, 25 (12) :2244-2248

[4] Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [J].

Kahn, Steven E. ;

Haffner, Steven M. ;

Heise, Mark A. ;

Herman, William H. ;

Holman, Rury R. ;

Jones, Nigel P. ;

Kravitz, Barbara G. ;

Lachin, John M. ;

O'Neill, M. Colleen ;

Zinman, Bernard ;

Viberti, Giancarlo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2427-2443

[5] Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy - A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [J].

Nathan, D. M. ;

Buse, J. B. ;

Davidson, M. B. ;

Heine, R. J. ;

Holman, R. R. ;

Sherwin, R. ;

Zinman, B. .

DIABETOLOGIA, 2006, 49 (08) :1711-1721

[6] Increased mortality in Type I diabetic patients using sulphonylurea and metformin in combination:: a population-based observational study [J].

Olsson, J ;

Lindberg, G ;

Gottsäter, M ;

Lindwall, K ;

Sjöstrand, Ä ;

Tisell, A ;

Melander, A .

DIABETOLOGIA, 2000, 43 (05) :558-560

[7] UGDP STUDY [J].

SALSBURG, DS .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 218 (11) :1704-+

[8] Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study [J].

Simpson, SH ;

Majumdar, SR ;

Tsuyuki, RT ;

Eurich, DT ;

Johnson, JA .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (02) :169-174

[9] Comment on:: !Evans JMM, !Ogston SA, !Emslie-Smith A, !Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes:: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936 [J].

Tayek, J. A. .

DIABETOLOGIA, 2006, 49 (11) :2807-2808

[10] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [J].

Turner, RC ;

Holman, RR ;

Stratton, IM ;

Cull, CA ;

Matthews, DR ;

Manley, SE ;

Frighi, V ;

Wright, D ;

Neil, A ;

Kohner, E ;

McElroy, H ;

Fox, C ;

Hadden, D .

LANCET, 1998, 352 (9131) :854-865

← 1 →